Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty in older adults with mild cognitive impairment
Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, frailty and serum level of the inflammatory index high-sensitivity C - reactive protein in the older adults with mild cognitive impairment
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty in older adults with mild cognitive impairment
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty and serum level of the inflammatory index high-sensitivity C - reactive protein in the older adults with mild cognitive impairment
مقایسه اثر مکمل یاری منیزیم و سین بیوتیک بر عملکرد شناختی، کیفیت زندگی، فرتوتی و سطح سرمی شاخص التهابی پروتئین واکنشیC- با حساسیت بالا در سالمندان مبتلا به اختلال شناختی خفیف
مقایسه اثر مکمل یاری منیزیم و سین بیوتیک بر عملکرد شناختی، کیفیت زندگی و فرتوتی در سالمندان مبتلا به اختلال شناختی خفیف
مقایسه اثر مکمل یاری منیزیم و سین بیوتیک بر عملکرد شناختی، کیفیت زندگی، فرتوتی و سطح سرمی شاخص التهابی پروتئین واکنشیC- با حساسیت بالافرتوتی در سالمندان مبتلا به اختلال شناختی خفیف
Participants will be selected by a simple random sampling from ّFarzanegan senior senter in Shiraz; after screening and confirming the disease and if they meet the study entry criteria, the informed consent form will be completed. Participants will be placed in one of three groups: magnesium intervention, synbiotic, and placebo by a random block method. outcomes will be evaluated at the beginning and end of the study. The duration of the intervention is 8 weeks. Also, in this study, participants and the researcher will be blinded.
Participants will be selected by simple random sampling from elderly care centers across Shiraz; after screening and confirming the disease, and if they meet the study entry criteria, the informed consent form will be completed. Participants will be placed in one of three groups: magnesium intervention, synbiotic, and placebo by a random block method. Outcomes will be evaluated at the beginning and end of the study. The duration of the intervention is 8 weeks. Also, in this study, participants and the researcher will be blinded.
Participants will be selected by a simple random sampling from ّFarzanegan senior senter inelderly care centers across Shiraz; after screening and confirming the disease, and if they meet the study entry criteria, the informed consent form will be completed. Participants will be placed in one of three groups: magnesium intervention, synbiotic, and placebo by a random block method. outcomesOutcomes will be evaluated at the beginning and end of the study. The duration of the intervention is 8 weeks. Also, in this study, participants and the researcher will be blinded.
شرکت کنندگان با روش نمونه گیری آسان از مرکز مراقبت از سالمندان فرزانگان ﺷﻬﺮ ﺷﯿﺮاز اﻧﺘﺨﺎب ﺧﻮاﻫﻨﺪ ﺷﺪ؛ ﭘﺲ از انجام غربالگری و ﺗﺎﯾﯿﺪ ﺑﯿﻤﺎری و درصورت داشتن معیار های ورود به مطالعه، ﻓﺮم رﺿﺎﯾﺖ آﮔﺎﻫﺎﻧﻪ توسط واﺟﺪﯾﻦ ﺷﺮاﯾﻂ ﺗﮑﻤﯿﻞ می گردد.شرکت کنندگان بر اساس روش بلاک بندی تصادفی در یکی از سه گروه مداخله منیزیم، سین بیوتیک و دارونما قرار خواهند گرفت و پیامد ها در ابتدا و انتهای مطالعه ارزیابی خواهد شد. طول مدت مداخله 8 هفته می باشد. همچنین در این مطالعه شرکت کنندگان و محقق کور خواهند شد.
شرکت کنندگان با روش نمونه گیری آسان از مراکز مراقبت از سالمندان ﺷﻬﺮ ﺷﯿﺮاز اﻧﺘﺨﺎب ﺧﻮاﻫﻨﺪ ﺷﺪ؛ ﭘﺲ از انجام غربالگری و ﺗﺎﯾﯿﺪ ﺑﯿﻤﺎری و درصورت داشتن معیار های ورود به مطالعه، ﻓﺮم رﺿﺎﯾﺖ آﮔﺎﻫﺎﻧﻪ توسط واﺟﺪﯾﻦ ﺷﺮاﯾﻂ ﺗﮑﻤﯿﻞ می گردد.شرکت کنندگان بر اساس روش بلاک بندی تصادفی در یکی از سه گروه مداخله منیزیم، سین بیوتیک و دارونما قرار خواهند گرفت و پیامد ها در ابتدا و انتهای مطالعه ارزیابی خواهد شد. طول مدت مداخله 8 هفته می باشد. همچنین در این مطالعه شرکت کنندگان و محقق کور خواهند شد.
شرکت کنندگان با روش نمونه گیری آسان از مرکزمراکز مراقبت از سالمندان فرزانگان ﺷﻬﺮ ﺷﯿﺮاز اﻧﺘﺨﺎب ﺧﻮاﻫﻨﺪ ﺷﺪ؛ ﭘﺲ از انجام غربالگری و ﺗﺎﯾﯿﺪ ﺑﯿﻤﺎری و درصورت داشتن معیار های ورود به مطالعه، ﻓﺮم رﺿﺎﯾﺖ آﮔﺎﻫﺎﻧﻪ توسط واﺟﺪﯾﻦ ﺷﺮاﯾﻂ ﺗﮑﻤﯿﻞ می گردد.شرکت کنندگان بر اساس روش بلاک بندی تصادفی در یکی از سه گروه مداخله منیزیم، سین بیوتیک و دارونما قرار خواهند گرفت و پیامد ها در ابتدا و انتهای مطالعه ارزیابی خواهد شد. طول مدت مداخله 8 هفته می باشد. همچنین در این مطالعه شرکت کنندگان و محقق کور خواهند شد.
Cognitive function, quality of life, frailty, serum level of the inflammatory index hs-CRP
Cognitive function, quality of life, frailty
Cognitive function, quality of life, frailty, serum level of the inflammatory index hs-CRP
عملکرد شناختی، کیفیت زندگی، فرتوتی، سطح سرمی شاخص التهابی پروتئین واکنشی -C با حساسیت بالا
عملکرد شناختی، کیفیت زندگی، فرتوتی
عملکرد شناختی، کیفیت زندگی، فرتوتی، سطح سرمی شاخص التهابی پروتئین واکنشی -C با حساسیت بالا
General information
empty
1. Removal of serum hs-CRP measurement:
Given that the implementation and sample collection phases of the study coincided with a period of critical and unstable social conditions, including the war and its related consequences, regular participant follow-up and laboratory visits became challenging. This issue was particularly relevant given the clinical trial design of the study, which requires continuous and regular follow-up of participants. In addition, budgetary constraints contributed to this limitation. Therefore, measurement of high-sensitivity C-reactive protein (hs-CRP) was removed from the study. Accordingly, the study title, objectives, problem statement, methodology, assessment tools, and other relevant sections of the protocol were reviewed and revised.
2. Removal of the PASE questionnaire and use of the third section of the Fried Frailty Scale:
Since both the Physical Activity Scale for the Elderly (PASE) and the Fried Frailty Scale assess physical activity and have considerable overlap in terms of their content, the PASE questionnaire was removed from the study to reduce the assessment burden and facilitate greater cooperation among older participants. Therefore, participants’ physical activity levels will be assessed solely using the third section of the Fried Frailty Scale. Accordingly, the section describing the instrument used to assess physical activity was reviewed and revised.
3. Expansion of the study recruitment sites:
To increase the diversity of the study population and reduce the potential for selection bias associated with recruiting participants from a single site, the study recruitment setting was expanded from one elderly-related center to all elderly care centers across Shiraz. Accordingly, individuals will undergo screening at centers across the city, and those who meet the criteria will be referred to the Imam Reza (AS) Clinic. Accordingly, the sections describing the study setting and participant recruitment procedures were revised and updated.
1. Removal of serum hs-CRP measurement: Given that the implementation and sample collection phases of the study coincided with a period of critical and unstable social conditions, including the war and its related consequences, regular participant follow-up and laboratory visits became challenging. This issue was particularly relevant given the clinical trial design of the study, which requires continuous and regular follow-up of participants. In addition, budgetary constraints contributed to this limitation. Therefore, measurement of high-sensitivity C-reactive protein (hs-CRP) was removed from the study. Accordingly, the study title, objectives, problem statement, methodology, assessment tools, and other relevant sections of the protocol were reviewed and revised. 2. Removal of the PASE questionnaire and use of the third section of the Fried Frailty Scale: Since both the Physical Activity Scale for the Elderly (PASE) and the Fried Frailty Scale assess physical activity and have considerable overlap in terms of their content, the PASE questionnaire was removed from the study to reduce the assessment burden and facilitate greater cooperation among older participants. Therefore, participants’ physical activity levels will be assessed solely using the third section of the Fried Frailty Scale. Accordingly, the section describing the instrument used to assess physical activity was reviewed and revised. 3. Expansion of the study recruitment sites: To increase the diversity of the study population and reduce the potential for selection bias associated with recruiting participants from a single site, the study recruitment setting was expanded from one elderly-related center to all elderly care centers across Shiraz. Accordingly, individuals will undergo screening at centers across the city, and those who meet the criteria will be referred to the Imam Reza (AS) Clinic. Accordingly, the sections describing the study setting and participant recruitment procedures were revised and updated.
empty
۱. حذف شاخص سرمی hs-CRP از مطالعه:
با توجه به همزمانی مرحله اجرای مطالعه و جمعآوری نمونهها با شرایط بحرانی و ناپایدار اجتماعی، از جمله جنگ و پیامدهای ناشی از آن، و با در نظر گرفتن ماهیت کارآزمایی بالینی و ضرورت پیگیری منظم شرکتکنندگان، مراجعه منظم آنان به آزمایشگاه با محدودیتهایی مواجه شد. همچنین، محدودیتهای بودجهای مطالعه نیز در این زمینه مؤثر بود. بنابراین، اندازهگیری شاخص سرمی پروتئین واکنشی C با حساسیت بالا (hs-CRP) از مطالعه حذف گردید. بر این اساس، عنوان مطالعه، اهداف، بیان مسئله، روش اجرا، ابزارهای ارزیابی و سایر بخشهای مرتبط بازنگری و اصلاح شدند.
۲. حذف پرسشنامه PASE و استفاده از بخش سوم مقیاس فرتوتی Fried:
با توجه به اینکه هر دو ابزار PASE و مقیاس فرتوتی Fried به ارزیابی فعالیت فیزیکی میپردازند و از نظر محتوایی دارای همپوشانی هستند، به منظور کاهش حجم ارزیابیها و جلب همکاری بیشتر سالمندان، پرسشنامه PASE از مطالعه حذف شد. بنابراین، میزان فعالیت فیزیکی شرکتکنندگان صرفاً با استفاده از بخش سوم مقیاس فرتوتی Fried ارزیابی خواهد شد. بر همین اساس، بخش مربوط به ابزار اندازهگیری فعالیت فیزیکی بازنگری و اصلاح گردید.
۳. گسترش محل نمونهگیری:
به منظور افزایش تنوع جامعه مورد مطالعه و کاهش احتمال سوگیری ناشی از انتخاب محل نمونهگیری، محل نمونهگیری از یک مرکز مرتبط با سالمندان به چندین مرکز مراقبت از سالمندان در سطح شهر شیراز گسترش یافت؛ بدین ترتیب که افراد در مراکز سطح شهر غربالگری شده و واجدین شرایط به درمانگاه امام رضا(ع) ارجاع داده خواهند شد. بر این اساس، بخش مربوط به محل و نحوه نمونهگیری اصلاح و بهروزرسانی شد.
۱. حذف شاخص سرمی hs-CRP از مطالعه: با توجه به همزمانی مرحله اجرای مطالعه و جمعآوری نمونهها با شرایط بحرانی و ناپایدار اجتماعی، از جمله جنگ و پیامدهای ناشی از آن، و با در نظر گرفتن ماهیت کارآزمایی بالینی و ضرورت پیگیری منظم شرکتکنندگان، مراجعه منظم آنان به آزمایشگاه با محدودیتهایی مواجه شد. همچنین، محدودیتهای بودجهای مطالعه نیز در این زمینه مؤثر بود. بنابراین، اندازهگیری شاخص سرمی پروتئین واکنشی C با حساسیت بالا (hs-CRP) از مطالعه حذف گردید. بر این اساس، عنوان مطالعه، اهداف، بیان مسئله، روش اجرا، ابزارهای ارزیابی و سایر بخشهای مرتبط بازنگری و اصلاح شدند. ۲. حذف پرسشنامه PASE و استفاده از بخش سوم مقیاس فرتوتی Fried: با توجه به اینکه هر دو ابزار PASE و مقیاس فرتوتی Fried به ارزیابی فعالیت فیزیکی میپردازند و از نظر محتوایی دارای همپوشانی هستند، به منظور کاهش حجم ارزیابیها و جلب همکاری بیشتر سالمندان، پرسشنامه PASE از مطالعه حذف شد. بنابراین، میزان فعالیت فیزیکی شرکتکنندگان صرفاً با استفاده از بخش سوم مقیاس فرتوتی Fried ارزیابی خواهد شد. بر همین اساس، بخش مربوط به ابزار اندازهگیری فعالیت فیزیکی بازنگری و اصلاح گردید. ۳. گسترش محل نمونهگیری: به منظور افزایش تنوع جامعه مورد مطالعه و کاهش احتمال سوگیری ناشی از انتخاب محل نمونهگیری، محل نمونهگیری از یک مرکز مرتبط با سالمندان به چندین مرکز مراقبت از سالمندان در سطح شهر شیراز گسترش یافت؛ بدین ترتیب که افراد در مراکز سطح شهر غربالگری شده و واجدین شرایط به درمانگاه امام رضا(ع) ارجاع داده خواهند شد. بر این اساس، بخش مربوط به محل و نحوه نمونهگیری اصلاح و بهروزرسانی شد.
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, frailty and inflammation
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, frailty and inflammationfrailty
مقایسه اثر مکمل منیزیم و سین بیوتیک بر عملکرد شناختی، کیفیت زندگی، فرتوتی و التهاب
مقایسه اثر مکمل منیزیم و سین بیوتیک بر عملکرد شناختی، کیفیت زندگی، فرتوتی
مقایسه اثر مکمل منیزیم و سین بیوتیک بر عملکرد شناختی، کیفیت زندگی، فرتوتی و التهاب
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, frailty and serum level of the inflammatory index high-sensitivity C - reactive protein in the older adults with mild cognitive impairment
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty in older adults with mild cognitive impairment
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty and serum level of the inflammatory index high-sensitivity C - reactive protein in the older adults with mild cognitive impairment
مقایسه اثر مکمل یاری منیزیم و سین بیوتیک بر عملکرد شناختی، کیفیت زندگی، فرتوتی و سطح سرمی شاخص التهابی پروتئین واکنشی-C با حساسیت بالا در سالمندان مبتلا به اختلال شناختی خفیف
مقایسه اثر مکمل یاری منیزیم و سین بیوتیک بر عملکرد شناختی، کیفیت زندگی و فرتوتی در سالمندان مبتلا به اختلال شناختی خفیف
مقایسه اثر مکمل یاری منیزیم و سین بیوتیک بر عملکرد شناختی، کیفیت زندگی، فرتوتی و سطح سرمی شاخص التهابی پروتئین واکنشی-C با حساسیت بالافرتوتی در سالمندان مبتلا به اختلال شناختی خفیف
Age 65 years and older
Suffering from mild cognitive impairment; means obtaining a score of 22 to 25 in the Mini-ACE cognitive function evaluation form
Ability and willingness to participate in the study
No smoking/alcohol and drug addiction
Absence of severe renal/hepatic/pulmonary insufficiency, uncontrolled diabetes, severe neurological or psychiatric disorders such as Bipolar disorder, Parkinson's disease, Dementia, unstable thyroid disease; Immune disorders such as HIV/AIDS
Not following specific diets (such as Ketogenic, Vegetarian, etc.)
No current use of medications that interact with magnesium, such as muscle relaxants, Penicillamine, Corticosteroids, Methyldopa, Magnesium-containing antacids, or other magnesium-containing products
Participants must have not taken antibiotics and probiotic, magnesium, and antioxidant supplements for at least 2 weeks prior to the start of the study
Age 65 years and older
Suffering from mild cognitive impairment, based on the Mini-ACE cognitive function evaluation form
Ability and willingness to participate in the study
No smoking/alcohol and drug addiction
Absence of severe renal/hepatic/pulmonary insufficiency, uncontrolled diabetes, severe neurological or psychiatric disorders such as Bipolar disorder, Parkinson's disease, Dementia, unstable thyroid disease; Immune disorders such as HIV/AIDS
Not following specific diets (such as Ketogenic, Vegetarian, etc.)
No current use of medications that interact with magnesium, such as muscle relaxants, Penicillamine, Corticosteroids, Methyldopa, Magnesium-containing antacids, or other magnesium-containing products
Participants must have not taken antibiotics and probiotic, magnesium, and antioxidant supplements for at least 2 weeks prior to the start of the study
Age 65 years and older Suffering from mild cognitive impairment; means obtaining a score of 22 to 25 in, based on the Mini-ACE cognitive function evaluation form Ability and willingness to participate in the study No smoking/alcohol and drug addiction Absence of severe renal/hepatic/pulmonary insufficiency, uncontrolled diabetes, severe neurological or psychiatric disorders such as Bipolar disorder, Parkinson's disease, Dementia, unstable thyroid disease; Immune disorders such as HIV/AIDS Not following specific diets (such as Ketogenic, Vegetarian, etc.) No current use of medications that interact with magnesium, such as muscle relaxants, Penicillamine, Corticosteroids, Methyldopa, Magnesium-containing antacids, or other magnesium-containing products Participants must have not taken antibiotics and probiotic, magnesium, and antioxidant supplements for at least 2 weeks prior to the start of the study
سن 65 سال و بیشتر
مبتلا به اختلال شناختی خفیف به معنی کسب نمره ۲۲ تا ۲۵ در فرم ارزیابی عملکرد شناختی Mini-ACE
توانایی و تمایل به شرکت در مطالعه
عدم اعتیاد به سیگار/الکل و مواد مخدر
عدم ابتلا به نارسایی های شدید کلیوی/کبدی/ ریوی، دیابت کنترل نشده، اختلالات عصبی یا روانی شدید مانند اختلال دوقطبی، بیماری پارکینسون ،زوال عقل، بیماری تیروئید ناپایدار؛ اختلالات ایمنی مانند HIV/AIDS
عدم پیروی از رژیم های غذایی خاص (مانند کتوژنیک، گیاهخواری و ...)
عدم استفاده فعلی از داروهایی که با منیزیم تداخل دارد مانند شل کننده های عضلانی، پنی سیلامین، کورتیکواستروئیدها، متیل دوپا، آنتی اسیدهای حاوی منیزیم یا سایر محصولات حاوی منیزیم
شرکت کنندگان باید حداقل 2 هفته قبل از شروع مطالعه، آنتی بیوتیک و مکمل های پروبیوتیک، منیزیم و آنتی اکسیدانی مصرف نکرده باشند
سن 65 سال و بیشتر
مبتلا به اختلال شناختی خفیف در فرم ارزیابی عملکرد شناختی Mini-ACE
توانایی و تمایل به شرکت در مطالعه
عدم اعتیاد به سیگار/الکل و مواد مخدر
عدم ابتلا به نارسایی های شدید کلیوی/کبدی/ ریوی، دیابت کنترل نشده، اختلالات عصبی یا روانی شدید مانند اختلال دوقطبی، بیماری پارکینسون ،زوال عقل، بیماری تیروئید ناپایدار؛ اختلالات ایمنی مانند HIV/AIDS
عدم پیروی از رژیم های غذایی خاص (مانند کتوژنیک، گیاهخواری و ...)
عدم استفاده فعلی از داروهایی که با منیزیم تداخل دارد مانند شل کننده های عضلانی، پنی سیلامین، کورتیکواستروئیدها، متیل دوپا، آنتی اسیدهای حاوی منیزیم یا سایر محصولات حاوی منیزیم
شرکت کنندگان باید حداقل 2 هفته قبل از شروع مطالعه، آنتی بیوتیک و مکمل های پروبیوتیک، منیزیم و آنتی اکسیدانی مصرف نکرده باشند
سن 65 سال و بیشتر مبتلا به اختلال شناختی خفیف به معنی کسب نمره ۲۲ تا ۲۵ در فرم ارزیابی عملکرد شناختی Mini-ACE توانایی و تمایل به شرکت در مطالعه عدم اعتیاد به سیگار/الکل و مواد مخدر عدم ابتلا به نارسایی های شدید کلیوی/کبدی/ ریوی، دیابت کنترل نشده، اختلالات عصبی یا روانی شدید مانند اختلال دوقطبی، بیماری پارکینسون ،زوال عقل، بیماری تیروئید ناپایدار؛ اختلالات ایمنی مانند HIV/AIDS عدم پیروی از رژیم های غذایی خاص (مانند کتوژنیک، گیاهخواری و ...) عدم استفاده فعلی از داروهایی که با منیزیم تداخل دارد مانند شل کننده های عضلانی، پنی سیلامین، کورتیکواستروئیدها، متیل دوپا، آنتی اسیدهای حاوی منیزیم یا سایر محصولات حاوی منیزیم شرکت کنندگان باید حداقل 2 هفته قبل از شروع مطالعه، آنتی بیوتیک و مکمل های پروبیوتیک، منیزیم و آنتی اکسیدانی مصرف نکرده باشند
Participants will be randomly assigned to three groups: magnesium intervention, synbiotic intervention, and control (A, B, C) based on the random blocking method using the Random Allocation Software with a ratio of 1:1:1.
This group assignment will be done by a person outside the study before the start of the design implementation process, and these sequences will be placed in sealed numbered envelopes by the same person in order to blind the researchers to the participant group by concealing the allocation.
After screening with a cognitive function assessment questionnaire and confirmation of mild cognitive impairment, participants will be referred to the research team and the thesis supervisor. After completing the evaluations and the initial questionnaires, an envelope will be opened according to the established order, and the assigned intervention group will be determined for the participating individual.
This randomization and groups will remain hidden from the researchers and participants until the statistical analysis are complete.
Participants will be randomly assigned to three groups: magnesium intervention, synbiotic intervention, and control (A, B, C) based on the random blocking method using the Random Allocation Software with a ratio of 1:1:1.
This group assignment will be done by a person outside the study before the start of the design implementation process, and these sequences will be placed in sealed numbered envelopes by the same person in order to blind the researchers to the participant group by concealing the allocation.
After screening with a cognitive function assessment questionnaire and confirmation of mild cognitive impairment, participants will be referred to the research team. After completing the evaluations and the initial questionnaires, an envelope will be opened according to the established order, and the assigned intervention group will be determined for the participating individual.
This randomization and the groups will remain hidden from the researchers and participants until the statistical analysis is complete.
Participants will be randomly assigned to three groups: magnesium intervention, synbiotic intervention, and control (A, B, C) based on the random blocking method using the Random Allocation Software with a ratio of 1:1:1. This group assignment will be done by a person outside the study before the start of the design implementation process, and these sequences will be placed in sealed numbered envelopes by the same person in order to blind the researchers to the participant group by concealing the allocation. After screening with a cognitive function assessment questionnaire and confirmation of mild cognitive impairment, participants will be referred to the research team and the thesis supervisor. After completing the evaluations and the initial questionnaires, an envelope will be opened according to the established order, and the assigned intervention group will be determined for the participating individual. This randomization and the groups will remain hidden from the researchers and participants until the statistical analysis areis complete.
شرکت کنندگان بر اساس روش بلاک بندی تصادفی با استفاده از نرم افزار Random Allocation Software با نسبت 1:1:1 به سه گروه مداخله منیزیم، مداخله سین بیوتیک و کنترل (A,B,C) تقسیم بندی خواهند گردید.
اﯾﻦ ﻧﺎم ﮔﺬاری ﮔﺮوه ﻫﺎ، ﭘﯿﺶ از ﺷﺮوع ﻓﺮاﯾﻨﺪ اﺟﺮای ﻃﺮح، ﺗﻮﺳﻂ ﻓﺮدی ﺧﺎرج از ﻣﻄﺎﻟﻌﻪ ﺻﻮرت ﺧﻮاﻫﺪ ﮔﺮﻓﺖ و اﯾﻦ ﺗﻮاﻟﯽ ﻫﺎ ﺗﻮﺳﻂ ﻫﻤﺎن ﻓﺮد ﺑﻪ ﺗﺮﺗﯿﺐ در ﭘﺎﮐﺖ ﻫﺎی ﺷﻤﺎره دار مهر و موم شده ﻗﺮار داده ﺧﻮاﻫﺪ ﺷﺪ ﺗﺎ ﺑﻪ وﺳﯿﻠﻪ ﭘﻨﻬﺎن ﺳﺎزی ﺗﺨﺼﯿﺺ، محققین ﻧﺴﺒﺖ ﺑﻪ ﮔﺮوه شرکت کنندگان، ﮐﻮرﺳﺎزی ﺷﺪه ﺑﺎﺷﻨﺪ.
ﺷﺮﮐﺖ ﮐﻨﻨﺪﮔﺎن پس از غربالگری با پرسشنامه ارزیابی عملکرد شناختی و ﺗﺎﯾﯿﺪ اختلال شناختی خفیف به ﺗﯿﻢ ﺗﺤﻘﯿﻖ ﻣﺮاﺟﻌﻪ ﻣﯽ ﮐﻨﻨﺪ. تیم تحقیق، ﺷﺮﮐﺖ ﮐﻨﻨﺪه را ﺑﺮ اﺳﺎس ﻣﻌﯿﺎرﻫﺎی ورود ﺑﺮرﺳﯽ می کند و در ﺻﻮرت ﺗﺎﯾﯿﺪ روش اجرای طرح برای فرد توضیح داده می شود. پس از این در صورت تمایل ﻓﺮد وارد ﻣﻄﺎﻟﻌﻪ ﺧﻮاﻫﺪ ﺷﺪ. ﭘﺲ از اﻧﺠﺎم ارزﯾﺎﺑﯽ ﻫﺎ و ﺗﮑﻤﯿﻞ ﭘﺮﺳﺸﻨﺎﻣﻪ ﻫﺎی اوﻟﯿﻪ، ﯾﮏ ﭘﺎﮐﺖ ﺑﺮ اﺳﺎس ﺗﺮﺗﯿﺐ ﺗﻌﯿﯿﻦ ﺷﺪه، ﺑﺮای ﻓﺮد ﺷﺮﮐﺖ ﮐﻨﻨﺪه ﺗﻮﺳﻂ داﻧﺸﺠﻮ ﺑﺎز ﺧﻮاﻫﺪ ﺷﺪ ﮐﻪ ﮔﺮوه ﻣﺪاﺧﻠﻪ ﺗﺨﺼﯿﺺ ﯾﺎﻓﺘﻪ ﻣﺸﺨﺺ ﻣﯽ ﺷﻮد.
اﯾﻦ ﺗﺼﺎدﻓﯽ ﺳﺎزی و ﮔﺮوه ﻫﺎ از ﻣﺤﻘﻘﺎن و ﺷﺮﮐﺖ ﮐﻨﻨﺪﮔﺎن ﺗﺎ زﻣﺎﻧﯽ ﮐﻪ ﺗﺠﺰﯾﻪ و ﺗﺤﻠﯿﻞ آﻣﺎری ﮐﺎﻣﻞ ﺷﻮد، ﭘﻨﻬﺎن ﺧﻮاﻫﺪ ﻣﺎﻧﺪ.
شرکت کنندگان بر اساس روش بلاک بندی تصادفی با استفاده از نرم افزار Random Allocation Software با نسبت 1:1:1 به سه گروه مداخله منیزیم، مداخله سین بیوتیک و کنترل (A,B,C) تقسیم بندی خواهند گردید.
اﯾﻦ ﻧﺎم ﮔﺬاری ﮔﺮوه ﻫﺎ، ﭘﯿﺶ از ﺷﺮوع ﻓﺮاﯾﻨﺪ اﺟﺮای ﻃﺮح، ﺗﻮﺳﻂ ﻓﺮدی ﺧﺎرج از ﻣﻄﺎﻟﻌﻪ ﺻﻮرت ﺧﻮاﻫﺪ ﮔﺮﻓﺖ و اﯾﻦ ﺗﻮاﻟﯽ ﻫﺎ ﺗﻮﺳﻂ ﻫﻤﺎن ﻓﺮد ﺑﻪ ﺗﺮﺗﯿﺐ در ﭘﺎﮐﺖ ﻫﺎی ﺷﻤﺎره دار مهر و موم شده ﻗﺮار داده ﺧﻮاﻫﺪ ﺷﺪ ﺗﺎ ﺑﻪ وﺳﯿﻠﻪ ﭘﻨﻬﺎن ﺳﺎزی ﺗﺨﺼﯿﺺ، محققین ﻧﺴﺒﺖ ﺑﻪ ﮔﺮوه شرکت کنندگان، ﮐﻮرﺳﺎزی ﺷﺪه ﺑﺎﺷﻨﺪ.
ﺷﺮﮐﺖ ﮐﻨﻨﺪﮔﺎن پس از غربالگری با پرسشنامه ارزیابی عملکرد شناختی و ﺗﺎﯾﯿﺪ اختلال شناختی خفیف به ﺗﯿﻢ ﺗﺤﻘﯿﻖ ﻣﺮاﺟﻌﻪ ﻣﯽ ﮐﻨﻨﺪ. تیم تحقیق، ﺷﺮﮐﺖ ﮐﻨﻨﺪه را ﺑﺮ اﺳﺎس ﻣﻌﯿﺎرﻫﺎی ورود ﺑﺮرﺳﯽ می کند و در ﺻﻮرت ﺗﺎﯾﯿﺪ روش اجرای طرح برای فرد توضیح داده می شود. پس از این در صورت تمایل ﻓﺮد وارد ﻣﻄﺎﻟﻌﻪ ﺧﻮاﻫﺪ ﺷﺪ. ﭘﺲ از اﻧﺠﺎم ارزﯾﺎﺑﯽ ﻫﺎ و ﺗﮑﻤﯿﻞ ﭘﺮﺳﺸﻨﺎﻣﻪ ﻫﺎی اوﻟﯿﻪ، ﯾﮏ ﭘﺎﮐﺖ ﺑﺮ اﺳﺎس ﺗﺮﺗﯿﺐ ﺗﻌﯿﯿﻦ ﺷﺪه، ﺑﺮای ﻓﺮد ﺷﺮﮐﺖ ﮐﻨﻨﺪه ﺗﻮﺳﻂ پژوهشگر ﺑﺎز ﺧﻮاﻫﺪ ﺷﺪ ﮐﻪ ﮔﺮوه ﻣﺪاﺧﻠﻪ ﺗﺨﺼﯿﺺ ﯾﺎﻓﺘﻪ ﻣﺸﺨﺺ ﻣﯽ ﺷﻮد.
اﯾﻦ ﺗﺼﺎدﻓﯽ ﺳﺎزی و ﮔﺮوه ﻫﺎ از ﻣﺤﻘﻘﺎن و ﺷﺮﮐﺖ ﮐﻨﻨﺪﮔﺎن ﺗﺎ زﻣﺎﻧﯽ ﮐﻪ ﺗﺠﺰﯾﻪ و ﺗﺤﻠﯿﻞ آﻣﺎری ﮐﺎﻣﻞ ﺷﻮد، ﭘﻨﻬﺎن ﺧﻮاﻫﺪ ﻣﺎﻧﺪ.
شرکت کنندگان بر اساس روش بلاک بندی تصادفی با استفاده از نرم افزار Random Allocation Software با نسبت 1:1:1 به سه گروه مداخله منیزیم، مداخله سین بیوتیک و کنترل (A,B,C) تقسیم بندی خواهند گردید. اﯾﻦ ﻧﺎم ﮔﺬاری ﮔﺮوه ﻫﺎ، ﭘﯿﺶ از ﺷﺮوع ﻓﺮاﯾﻨﺪ اﺟﺮای ﻃﺮح، ﺗﻮﺳﻂ ﻓﺮدی ﺧﺎرج از ﻣﻄﺎﻟﻌﻪ ﺻﻮرت ﺧﻮاﻫﺪ ﮔﺮﻓﺖ و اﯾﻦ ﺗﻮاﻟﯽ ﻫﺎ ﺗﻮﺳﻂ ﻫﻤﺎن ﻓﺮد ﺑﻪ ﺗﺮﺗﯿﺐ در ﭘﺎﮐﺖ ﻫﺎی ﺷﻤﺎره دار مهر و موم شده ﻗﺮار داده ﺧﻮاﻫﺪ ﺷﺪ ﺗﺎ ﺑﻪ وﺳﯿﻠﻪ ﭘﻨﻬﺎن ﺳﺎزی ﺗﺨﺼﯿﺺ، محققین ﻧﺴﺒﺖ ﺑﻪ ﮔﺮوه شرکت کنندگان، ﮐﻮرﺳﺎزی ﺷﺪه ﺑﺎﺷﻨﺪ. ﺷﺮﮐﺖ ﮐﻨﻨﺪﮔﺎن پس از غربالگری با پرسشنامه ارزیابی عملکرد شناختی و ﺗﺎﯾﯿﺪ اختلال شناختی خفیف به ﺗﯿﻢ ﺗﺤﻘﯿﻖ ﻣﺮاﺟﻌﻪ ﻣﯽ ﮐﻨﻨﺪ. تیم تحقیق، ﺷﺮﮐﺖ ﮐﻨﻨﺪه را ﺑﺮ اﺳﺎس ﻣﻌﯿﺎرﻫﺎی ورود ﺑﺮرﺳﯽ می کند و در ﺻﻮرت ﺗﺎﯾﯿﺪ روش اجرای طرح برای فرد توضیح داده می شود. پس از این در صورت تمایل ﻓﺮد وارد ﻣﻄﺎﻟﻌﻪ ﺧﻮاﻫﺪ ﺷﺪ. ﭘﺲ از اﻧﺠﺎم ارزﯾﺎﺑﯽ ﻫﺎ و ﺗﮑﻤﯿﻞ ﭘﺮﺳﺸﻨﺎﻣﻪ ﻫﺎی اوﻟﯿﻪ، ﯾﮏ ﭘﺎﮐﺖ ﺑﺮ اﺳﺎس ﺗﺮﺗﯿﺐ ﺗﻌﯿﯿﻦ ﺷﺪه، ﺑﺮای ﻓﺮد ﺷﺮﮐﺖ ﮐﻨﻨﺪه ﺗﻮﺳﻂ داﻧﺸﺠﻮپژوهشگر ﺑﺎز ﺧﻮاﻫﺪ ﺷﺪ ﮐﻪ ﮔﺮوه ﻣﺪاﺧﻠﻪ ﺗﺨﺼﯿﺺ ﯾﺎﻓﺘﻪ ﻣﺸﺨﺺ ﻣﯽ ﺷﻮد. اﯾﻦ ﺗﺼﺎدﻓﯽ ﺳﺎزی و ﮔﺮوه ﻫﺎ از ﻣﺤﻘﻘﺎن و ﺷﺮﮐﺖ ﮐﻨﻨﺪﮔﺎن ﺗﺎ زﻣﺎﻧﯽ ﮐﻪ ﺗﺠﺰﯾﻪ و ﺗﺤﻠﯿﻞ آﻣﺎری ﮐﺎﻣﻞ ﺷﻮد، ﭘﻨﻬﺎن ﺧﻮاﻫﺪ ﻣﺎﻧﺪ.
In the first phase of the study, the supplements and placebo are placed in capsules that are similar in color, size, and shape and packaged. In this phase, the capsules are labeled with the Latin contract names A, B, and C. In the intervention phase, the random assignment sequence is also identified with the same names by a person outside the study.
Therefore, during the study, the participants and the student implementing the project, who is in charge of carrying out the clinical phase, clinical evaluations, follow-up of laboratory tests and data analysis, will be blinded to the assigned group and the intervention in each group.
In the first phase of the study, the supplements and placebo are placed in capsules that are similar in color, size, and shape and are packaged. In this phase, the capsules are labeled with the Latin contract names A, B, and C. In the intervention phase, the random assignment sequence is also identified with the same names by a person outside the study.
Therefore, during the study, the participants and the researcher, who is in charge of carrying out the clinical phase, clinical evaluations, follow-up of laboratory tests, and data analysis, will be blinded to the assigned group and the intervention in each group.
In the first phase of the study, the supplements and placebo are placed in capsules that are similar in color, size, and shape and are packaged. In this phase, the capsules are labeled with the Latin contract names A, B, and C. In the intervention phase, the random assignment sequence is also identified with the same names by a person outside the study. Therefore, during the study, the participants and the student implementing the projectresearcher, who is in charge of carrying out the clinical phase, clinical evaluations, follow-up of laboratory tests, and data analysis, will be blinded to the assigned group and the intervention in each group.
درﻣﺮﺣﻠﻪ اول ﻣﻄﺎﻟﻌﻪ، ﻣﮑﻤﻞ ﻫﺎ و داروﻧﻤﺎ درﮐﭙﺴﻮل ﻫﺎﯾﯽ ﮐﻪ از ﻟﺤﺎظ رﻧﮓ و اﻧﺪازه و ﺷﮑﻞ ﺷﺒﯿﻪ ﺑﻪ ﯾﮑﺪﯾﮕﺮ ﺑﺎﺷﻨﺪ ﺟﺎﯾﮕﺬاری و ﺑﺴﺘﻪ ﺑﻨﺪی می شوند. در اﯾﻦ ﻣﺮﺣﻠﻪ ﮐﭙﺴﻮل ﻫﺎ با ﻧﺎم ﻫﺎی ﻗﺮاردادی ﻻﺗﯿﻦ A و B و C ﻧﺎم ﮔﺬاری ﻣﯽ ﺷﻮﻧﺪ. در ﻓﺎز ﻣﺪاﺧﻠﻪ ، ﺗﻮاﻟﯽ ﺗﺨﺼﯿﺺ ﺗﺼﺎدﻓﯽ ﻧﯿﺰ ﺑﺎ ﻫﻤﯿﻦ ﻧﺎم ﻫﺎ ﺗﻮﺳﻂ ﻓﺮد ﺧﺎرج از ﻣﻄﺎﻟﻌﻪ ﻣﺸﺨﺺ ﻣﯽ ﺷﻮد.
ﺑﻨﺎﺑﺮاﯾﻦ در ﻃﻮل ﻣﻄﺎﻟﻌﻪ، ﺷﺮﮐﺖ ﮐﻨﻨﺪﮔﺎن و داﻧﺸﺠﻮی ﻣﺠﺮی ﻃﺮح ﮐﻪ وﻇﯿﻔﻪ اﺟﺮای ﻓﺎز ﺑﺎﻟﯿﻨﯽ، ارزﯾﺎﺑﯽ ﻫﺎی ﺑﺎﻟﯿﻨﯽ، پیگیری اﻧﺠﺎم ﺗﺴﺖ ﻫﺎی آزﻣﺎﯾﺸﮕﺎﻫﯽ و آﻧﺎﻟﯿﺰ داده ﻫﺎ را ﺑﺮﻋﻬﺪه دارد ﻧﺴﺒﺖ ﺑﻪ ﮔﺮوه اﺧﺘﺼﺎص ﯾﺎﻓﺘﻪ و ﻣﺪاﺧﻠﻪ ﺻﻮرت ﮔﺮﻓﺘﻪ در ﻫﺮ ﮔﺮوه، ﮐﻮرﺳﺎزی ﺧﻮاﻫﻨﺪ ﺷﺪ.
درﻣﺮﺣﻠﻪ اول ﻣﻄﺎﻟﻌﻪ، ﻣﮑﻤﻞ ﻫﺎ و داروﻧﻤﺎ درﮐﭙﺴﻮل ﻫﺎﯾﯽ ﮐﻪ از ﻟﺤﺎظ رﻧﮓ و اﻧﺪازه و ﺷﮑﻞ ﺷﺒﯿﻪ ﺑﻪ ﯾﮑﺪﯾﮕﺮ ﺑﺎﺷﻨﺪ ﺟﺎﯾﮕﺬاری و ﺑﺴﺘﻪ ﺑﻨﺪی می شوند. در اﯾﻦ ﻣﺮﺣﻠﻪ ﮐﭙﺴﻮل ﻫﺎ با ﻧﺎم ﻫﺎی ﻗﺮاردادی ﻻﺗﯿﻦ A و B و C ﻧﺎم ﮔﺬاری ﻣﯽ ﺷﻮﻧﺪ. در ﻓﺎز ﻣﺪاﺧﻠﻪ ، ﺗﻮاﻟﯽ ﺗﺨﺼﯿﺺ ﺗﺼﺎدﻓﯽ ﻧﯿﺰ ﺑﺎ ﻫﻤﯿﻦ ﻧﺎم ﻫﺎ ﺗﻮﺳﻂ ﻓﺮد ﺧﺎرج از ﻣﻄﺎﻟﻌﻪ ﻣﺸﺨﺺ ﻣﯽ ﺷﻮد.
ﺑﻨﺎﺑﺮاﯾﻦ در ﻃﻮل ﻣﻄﺎﻟﻌﻪ، ﺷﺮﮐﺖ ﮐﻨﻨﺪﮔﺎن و محقق ﻣﺠﺮی ﻃﺮح ﮐﻪ وﻇﯿﻔﻪ اﺟﺮای ﻓﺎز ﺑﺎﻟﯿﻨﯽ، ارزﯾﺎﺑﯽ ﻫﺎی ﺑﺎﻟﯿﻨﯽ و آﻧﺎﻟﯿﺰ داده ﻫﺎ را ﺑﺮﻋﻬﺪه دارد ﻧﺴﺒﺖ ﺑﻪ ﮔﺮوه اﺧﺘﺼﺎص ﯾﺎﻓﺘﻪ و ﻣﺪاﺧﻠﻪ ﺻﻮرت ﮔﺮﻓﺘﻪ در ﻫﺮ ﮔﺮوه، ﮐﻮرﺳﺎزی ﺧﻮاﻫﻨﺪ ﺷﺪ.
درﻣﺮﺣﻠﻪ اول ﻣﻄﺎﻟﻌﻪ، ﻣﮑﻤﻞ ﻫﺎ و داروﻧﻤﺎ درﮐﭙﺴﻮل ﻫﺎﯾﯽ ﮐﻪ از ﻟﺤﺎظ رﻧﮓ و اﻧﺪازه و ﺷﮑﻞ ﺷﺒﯿﻪ ﺑﻪ ﯾﮑﺪﯾﮕﺮ ﺑﺎﺷﻨﺪ ﺟﺎﯾﮕﺬاری و ﺑﺴﺘﻪ ﺑﻨﺪی می شوند. در اﯾﻦ ﻣﺮﺣﻠﻪ ﮐﭙﺴﻮل ﻫﺎ با ﻧﺎم ﻫﺎی ﻗﺮاردادی ﻻﺗﯿﻦ A و B و C ﻧﺎم ﮔﺬاری ﻣﯽ ﺷﻮﻧﺪ. در ﻓﺎز ﻣﺪاﺧﻠﻪ ، ﺗﻮاﻟﯽ ﺗﺨﺼﯿﺺ ﺗﺼﺎدﻓﯽ ﻧﯿﺰ ﺑﺎ ﻫﻤﯿﻦ ﻧﺎم ﻫﺎ ﺗﻮﺳﻂ ﻓﺮد ﺧﺎرج از ﻣﻄﺎﻟﻌﻪ ﻣﺸﺨﺺ ﻣﯽ ﺷﻮد. ﺑﻨﺎﺑﺮاﯾﻦ در ﻃﻮل ﻣﻄﺎﻟﻌﻪ، ﺷﺮﮐﺖ ﮐﻨﻨﺪﮔﺎن و داﻧﺸﺠﻮیمحقق ﻣﺠﺮی ﻃﺮح ﮐﻪ وﻇﯿﻔﻪ اﺟﺮای ﻓﺎز ﺑﺎﻟﯿﻨﯽ، ارزﯾﺎﺑﯽ ﻫﺎی ﺑﺎﻟﯿﻨﯽ، پیگیری اﻧﺠﺎم ﺗﺴﺖ ﻫﺎی آزﻣﺎﯾﺸﮕﺎﻫﯽ و آﻧﺎﻟﯿﺰ داده ﻫﺎ را ﺑﺮﻋﻬﺪه دارد ﻧﺴﺒﺖ ﺑﻪ ﮔﺮوه اﺧﺘﺼﺎص ﯾﺎﻓﺘﻪ و ﻣﺪاﺧﻠﻪ ﺻﻮرت ﮔﺮﻓﺘﻪ در ﻫﺮ ﮔﺮوه، ﮐﻮرﺳﺎزی ﺧﻮاﻫﻨﺪ ﺷﺪ.
Serum level of high-sensitivity C-reactive protein
empty
Serum level of high-sensitivity C-reactive protein
سطح سرمی پروتئین واکنشیC- با حساسیت بالا
empty
سطح سرمی پروتئین واکنشیC- با حساسیت بالا
Measurement of serum levels of high-sensitivity C-reactive protein before the start of the intervention and 8 weeks later (end of study)
empty
Measurement of serum levels of high-sensitivity C-reactive protein before the start of the intervention and 8 weeks later (end of study)
اندازه گیری سطح سرمی پروتئین واکنشیC- با حساسیت بالا قبل از شروع مداخله و 8 هفته بعد ( انتهای مطالعه)
empty
اندازه گیری سطح سرمی پروتئین واکنشیC- با حساسیت بالا قبل از شروع مداخله و 8 هفته بعد ( انتهای مطالعه)
Through a blood test and ELISA method
empty
Through a blood test and ELISA method
از طریق آزمایش خون و به روش الایزا
empty
از طریق آزمایش خون و به روش الایزا
Intervention groups
#1
First intervention group: In this group, individuals will receive one capsule containing 300 mg of elemental magnesium (500 mg of magnesium in the form of magnesium oxide) daily for 8 weeks. Magnesium supplements will be prepared from Jalinous Pharmaceutical Company in the form of magnesium oxide powder and encapsulated by Shiraz Faculty of Pharmacy.
First intervention group: In this group, individuals will receive one capsule containing 300 mg of elemental magnesium (500 mg of magnesium in the form of magnesium oxide) daily for 8 weeks. Magnesium supplements will be prepared by Jalinous Pharmaceutical Company in the form of magnesium oxide powder and encapsulated by the Shiraz Faculty of Pharmacy.
First intervention group: In this group, individuals will receive one capsule containing 300 mg of elemental magnesium (500 mg of magnesium in the form of magnesium oxide) daily for 8 weeks. Magnesium supplements will be prepared fromby Jalinous Pharmaceutical Company in the form of magnesium oxide powder and encapsulated by the Shiraz Faculty of Pharmacy.
Recruitment centers
#1
Name of recruitment center - English: Farzanegan Senior Center, Shiraz
Name of recruitment center - Persian: مرکز سالمندان فرزانگان شیراز
Full name of responsible person - English: Shahzad Etemad
Full name of responsible person - Persian: شه زاد اعتماد
Street address - English: four hundred meters after the Science and Technology Park, Fanavari Street, end of Arian Town, Sanayi Blvd. (Mirza Shirazi, Dr. Hesabi Alley 22), Shiraz
Street address - Persian: شیراز، بلوار صنایع (میرزای شیرازی، کوچه 22 دکتر حسابی) ، انتهای شهرک آرین، خیابان فناوری، چهار صد متر بعد از پارک علم و فناوری
City - English: Shiraz
City - Persian: شیراز
Province: Fars
Country: Iran (Islamic Republic of)
Postal code: 7197687876
Phone: +98 71 9101 1021
Fax:
Email: farzanegan.shz@gmail.com
Web page address: https://www.farzanegan24.com
Name of recruitment center - English: Imam Reza (AS) Specialized and Sub-specialized Clinic, Shiraz
Name of recruitment center - Persian: درمانگاه تخصصی و فوق تخصصی امام رضا (ع)، شیراز
Full name of responsible person - English: Afsane Ahmadi
Full name of responsible person - Persian: افسانه احمدی
Street address - English: Namazi Square
Street address - Persian: میدان نمازی
City - English: Shiraz
City - Persian: شیراز
Province: Fars
Country: Iran (Islamic Republic of)
Postal code: 7134814734
Phone: +98 71 3212 7000
Fax:
Email: ahmadi.afsane@gmail.com
Web page address:
Name of recruitment center - English: Farzanegan Senior CenterImam Reza (AS) Specialized and Sub-specialized Clinic, Shiraz Name of recruitment center - Persian: مرکز سالمندان فرزانگاندرمانگاه تخصصی و فوق تخصصی امام رضا (ع)، شیراز Full name of responsible person - English: Shahzad EtemadAfsane Ahmadi Full name of responsible person - Persian: شه زاد اعتمادافسانه احمدی Street address - English: four hundred meters after the Science and Technology Park, Fanavari Street, end of Arian Town, Sanayi Blvd. (Mirza Shirazi, Dr. Hesabi Alley 22), ShirazNamazi Square Street address - Persian: شیراز، بلوار صنایع (میرزای شیرازی، کوچه 22 دکتر حسابی) ، انتهای شهرک آرین، خیابان فناوری، چهار صد متر بعد از پارک علم و فناوریمیدان نمازی City - English: Shiraz City - Persian: شیراز Province: Fars Country: Iran (Islamic Republic of) Postal code: 71976878767134814734 Phone: +98 71 9101 10213212 7000 Fax: Email: farzanegan.shzahmadi.afsane@gmail.com Web page address: https://www.farzanegan24.com
Sponsors / Funding sources
#1
Performance-based grant
Performance-based grant
گرنت عملکرد محور
گرنت عملکرد محور
Person responsible for scientific inquiries
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: Afsane Ahmadi
Full name of responsible person - Persian: افسانه احمدی
Position - English: Assistant professor, Faculty member / School of Nutrition and Food Sciences / Shiraz University of M
Position - Persian: استادیار، عضو هیئت علمی / دانشکده تغذیه و علوم غذایی / دانشگاه علوم پزشکی شیراز
Latest degree: phd
Area of specialty/work: 34
Area of specialty/work title - English:
Area of specialty/work title - Persian:
Street address - English: School of Nutrition and Food Sciences, in front of Bargh Sports Club, Razi Blvd, Shiraz
Street address - Persian: شیراز- بلوار رازی- روبروی باشگاه ورزشی برق- دانشکده تغذیه و علوم غذایی
City - English: Shiraz
City - Persian: شیراز
Province: Fars
Province - English:
Province - Persian:
contact.provinces_available: 1
Country: Iran (Islamic Republic of)
Postal code: 7153675500
Phone: +98 71 3725 1001 -8
Mobile: +98 917 314 9916
Fax:
Email: ahmadi.afsane@gmail.com
Web page address:
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: Afsane Ahmadi
Full name of responsible person - Persian: افسانه احمدی
Position - English: Assistant professor, Faculty member / School of Nutrition and Food Sciences / Shiraz University of M
Position - Persian: استادیار، عضو هیئت علمی / دانشکده تغذیه و علوم غذایی / دانشگاه علوم پزشکی شیراز
Latest degree: phd
Area of specialty/work: 34
Area of specialty/work title - English:
Area of specialty/work title - Persian:
Street address - English: School of Nutrition and Food Sciences, in front of Bargh Sports Club, Razi Blvd, Shiraz
Street address - Persian: شیراز- بلوار رازی- روبروی باشگاه ورزشی برق- دانشکده تغذیه و علوم غذایی
City - English: Shiraz
City - Persian: شیراز
Province: Fars
Province - English:
Province - Persian:
contact.provinces_available: 1
Country: Iran (Islamic Republic of)
Postal code: 7153675500
Phone: +98 71372510018
Mobile: +98 917 314 9916
Fax:
Email: ahmadi.afsane@gmail.com
Web page address:
Name of organization / entity - English: Name of organization / entity - Persian: Full name of responsible person - English: Afsane Ahmadi Full name of responsible person - Persian: افسانه احمدی Position - English: Assistant professor, Faculty member / School of Nutrition and Food Sciences / Shiraz University of M Position - Persian: استادیار، عضو هیئت علمی / دانشکده تغذیه و علوم غذایی / دانشگاه علوم پزشکی شیراز Latest degree: phd Area of specialty/work: 34 Area of specialty/work title - English: Area of specialty/work title - Persian: Street address - English: School of Nutrition and Food Sciences, in front of Bargh Sports Club, Razi Blvd, Shiraz Street address - Persian: شیراز- بلوار رازی- روبروی باشگاه ورزشی برق- دانشکده تغذیه و علوم غذایی City - English: Shiraz City - Persian: شیراز Province: Fars Province - English: Province - Persian: contact.provinces_available: 1 Country: Iran (Islamic Republic of) Postal code: 7153675500 Phone: +98 71 3725 1001 -871372510018 Mobile: +98 917 314 9916 Fax: Email: ahmadi.afsane@gmail.com Web page address:
Protocol summary
Study aim
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty in older adults with mild cognitive impairment
Design
A clinical trial with control group, double-blind, randomized, parallel-group on 63 participants. Random Allocation Software was used for randomization.
Settings and conduct
Participants will be selected by simple random sampling from elderly care centers across Shiraz; after screening and confirming the disease, and if they meet the study entry criteria, the informed consent form will be completed. Participants will be placed in one of three groups: magnesium intervention, synbiotic, and placebo by a random block method. Outcomes will be evaluated at the beginning and end of the study. The duration of the intervention is 8 weeks. Also, in this study, participants and the researcher will be blinded.
Participants/Inclusion and exclusion criteria
Inclusion criteria included: age 65 years and older, mild cognitive impairment, no severe renal/liver/pulmonary insufficiency, no uncontrolled diabetes, no severe neurological or psychiatric disorders, no adherence to special diets, no current use of medications that interact with magnesium. Exclusion criteria included changes in usual diet and medication, initiation of antibiotic therapy, occurrence of any side effects that stopped with discontinuation of the intervention, adherence of less than 80% and unwillingness to continue cooperation.
Intervention groups
Eligible people are placed in one of the following groups by random blocking method:
group1: taking a capsule containing 300 mg of elemental magnesium daily. Group 2: taking a synbiotic capsule daily. Group 3: taking a placebo
Main outcome variables
Cognitive function, quality of life, frailty
General information
Reason for update
1. Removal of serum hs-CRP measurement:
Given that the implementation and sample collection phases of the study coincided with a period of critical and unstable social conditions, including the war and its related consequences, regular participant follow-up and laboratory visits became challenging. This issue was particularly relevant given the clinical trial design of the study, which requires continuous and regular follow-up of participants. In addition, budgetary constraints contributed to this limitation. Therefore, measurement of high-sensitivity C-reactive protein (hs-CRP) was removed from the study. Accordingly, the study title, objectives, problem statement, methodology, assessment tools, and other relevant sections of the protocol were reviewed and revised.
2. Removal of the PASE questionnaire and use of the third section of the Fried Frailty Scale:
Since both the Physical Activity Scale for the Elderly (PASE) and the Fried Frailty Scale assess physical activity and have considerable overlap in terms of their content, the PASE questionnaire was removed from the study to reduce the assessment burden and facilitate greater cooperation among older participants. Therefore, participants’ physical activity levels will be assessed solely using the third section of the Fried Frailty Scale. Accordingly, the section describing the instrument used to assess physical activity was reviewed and revised.
3. Expansion of the study recruitment sites:
To increase the diversity of the study population and reduce the potential for selection bias associated with recruiting participants from a single site, the study recruitment setting was expanded from one elderly-related center to all elderly care centers across Shiraz. Accordingly, individuals will undergo screening at centers across the city, and those who meet the criteria will be referred to the Imam Reza (AS) Clinic. Accordingly, the sections describing the study setting and participant recruitment procedures were revised and updated.
Acronym
IRCT registration information
IRCT registration number:IRCT20250317065109N1
Registration date:2025-04-02, 1404/01/13
Registration timing:prospective
Last update:2026-09-17, 1405/06/26
Update count:1
Registration date
2025-04-02, 1404/01/13
Registrant information
Name
Rahil Ranjbar
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 71 5357 9434
Email address
rahilranjbar9@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2025-04-21, 1404/02/01
Expected recruitment end date
2025-09-22, 1404/06/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty in older adults with mild cognitive impairment
Public title
Comparison of the effect of magnesium and synbiotic supplementation on cognitive function, quality of life, and frailty
Purpose
Supportive
Inclusion/Exclusion criteria
Inclusion criteria:
Age 65 years and older
Suffering from mild cognitive impairment, based on the Mini-ACE cognitive function evaluation form
Ability and willingness to participate in the study
No smoking/alcohol and drug addiction
Absence of severe renal/hepatic/pulmonary insufficiency, uncontrolled diabetes, severe neurological or psychiatric disorders such as Bipolar disorder, Parkinson's disease, Dementia, unstable thyroid disease; Immune disorders such as HIV/AIDS
Not following specific diets (such as Ketogenic, Vegetarian, etc.)
No current use of medications that interact with magnesium, such as muscle relaxants, Penicillamine, Corticosteroids, Methyldopa, Magnesium-containing antacids, or other magnesium-containing products
Participants must have not taken antibiotics and probiotic, magnesium, and antioxidant supplements for at least 2 weeks prior to the start of the study
Exclusion criteria:
Changes in usual diet and medication
Starting antibiotic therapy
The occurrence of any side effects that stops when the intervention is discontinued.
Less than 80% adherence to supplement use
Unwillingness to continue cooperation
Age
From 65 years old
Gender
Both
Phase
N/A
Groups that have been masked
Participant
Investigator
Outcome assessor
Data analyser
Sample size
Target sample size:
63
Randomization (investigator's opinion)
Randomized
Randomization description
Participants will be randomly assigned to three groups: magnesium intervention, synbiotic intervention, and control (A, B, C) based on the random blocking method using the Random Allocation Software with a ratio of 1:1:1.
This group assignment will be done by a person outside the study before the start of the design implementation process, and these sequences will be placed in sealed numbered envelopes by the same person in order to blind the researchers to the participant group by concealing the allocation.
After screening with a cognitive function assessment questionnaire and confirmation of mild cognitive impairment, participants will be referred to the research team. After completing the evaluations and the initial questionnaires, an envelope will be opened according to the established order, and the assigned intervention group will be determined for the participating individual.
This randomization and the groups will remain hidden from the researchers and participants until the statistical analysis is complete.
Blinding (investigator's opinion)
Double blinded
Blinding description
In the first phase of the study, the supplements and placebo are placed in capsules that are similar in color, size, and shape and are packaged. In this phase, the capsules are labeled with the Latin contract names A, B, and C. In the intervention phase, the random assignment sequence is also identified with the same names by a person outside the study.
Therefore, during the study, the participants and the researcher, who is in charge of carrying out the clinical phase, clinical evaluations, follow-up of laboratory tests, and data analysis, will be blinded to the assigned group and the intervention in each group.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Shiraz University of Medical Sciences
Street address
Shiraz University of Medical Sciences Central Building, in front of Palestine, Zand Street
City
Shiraz
Province
Fars
Postal code
7134814336
Approval date
2025-02-16, 1403/11/28
Ethics committee reference number
IR.SUMS.SCHEANUT.REC.1403.119
Health conditions studied
1
Description of health condition studied
Mild cognitive impairment
ICD-10 code
G31.84
ICD-10 code description
Mild cognitive impairment, so stated
Primary outcomes
1
Description
Cognitive function score in the Mini-Addenbrooke’s Cognitive Examination (M-ACE) questionnaire
Timepoint
Cognitive function assessment before the start of the intervention and 8 weeks later (end of the study)
Quality of life score in the Older People's Quality of Life questionnaire (OPQOL-brief)
Timepoint
Quality of life assessment before the start of the intervention and 8 weeks later (end of the study)
Method of measurement
Older People's Quality of Life questionnaire-brief version (OPQOL-brief)
2
Description
Frailty score in the Frailty Syndrome Checklist 5-Items in Frail Older Adults in Iran (Fried's Five-Point Frailty Test)
Timepoint
Frailty assessment before the start of the intervention and 8 weeks later (end of the study)
Method of measurement
Frailty score in the Frailty Syndrome Checklist 5-Items in Frail Older Adults in Iran (Fried's Five-Point Frailty Test)
Intervention groups
1
Description
First intervention group: In this group, individuals will receive one capsule containing 300 mg of elemental magnesium (500 mg of magnesium in the form of magnesium oxide) daily for 8 weeks. Magnesium supplements will be prepared by Jalinous Pharmaceutical Company in the form of magnesium oxide powder and encapsulated by the Shiraz Faculty of Pharmacy.
Category
Treatment - Other
2
Description
Second intervention group: In this group, individuals will receive one synbiotic capsule daily for 8 weeks. The synbiotic supplement will be provided in capsule form by the Zist Takhmir Pharmaceutical Company (Familact®). This supplement contains 109 CFU of probiotics including Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium bifidum, Streptococcus thermophilus, and 74 mg of fructooligosaccharide in synbiotic form.
Category
Treatment - Other
3
Description
Control group: In this group, individuals will receive a placebo in capsule form that is similar in appearance to the intervention group for 8 weeks. Also, the placebo will be provided in capsule form by Zist Takhmir Pharmaceutical Company. The content of the placebo will be mostly maltodextrin and lactose monohydrate.
Category
Placebo
Recruitment centers
1
Recruitment center
Name of recruitment center
Imam Reza (AS) Specialized and Sub-specialized Clinic, Shiraz
Full name of responsible person
Afsane Ahmadi
Street address
Namazi Square
City
Shiraz
Province
Fars
Postal code
7134814734
Phone
+98 71 3212 7000
Email
ahmadi.afsane@gmail.com
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Hamid Mohammadi
Street address
Shiraz University of Medical Sciences central building, in front of Palestine St., Zand St.
City
Shiraz
Province
Fars
Postal code
7134814336
Phone
+98 71 3235 7282
Fax
Email
mohammadi@sums.ac.ir
Web page address
https://research.sums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shiraz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Rahil Ranjbar
Position
Master's degree student
Latest degree
Bachelor
Other areas of specialty/work
Nutrition
Street address
Alley 19, Yas street, Ayatollah Nassabeh Town, Darab
City
Darab
Province
Fars
Postal code
7481315134
Phone
+98 71 5357 9434
Email
Rahilranjbar9@gmail.com
Person responsible for scientific inquiries
Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Afsane Ahmadi
Position
Assistant professor, Faculty member / School of Nutrition and Food Sciences / Shiraz University of M
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
School of Nutrition and Food Sciences, in front of Bargh Sports Club, Razi Blvd, Shiraz
City
Shiraz
Province
Fars
Postal code
7153675500
Phone
+98 71372510018
Email
ahmadi.afsane@gmail.com
Person responsible for updating data
Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Rahil Ranjbar
Position
Master's degree student
Latest degree
Bachelor
Other areas of specialty/work
Nutrition
Street address
Alley 19, Yas street, Ayatollah Nassabeh Town, Darab
City
Darab
Province
Fars
Postal code
7481315134
Phone
+98 71 5357 9434
Email
Rahilranjbar9@gmail.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available